08.01.2021 • NewsSolvay

Solvay Sells Surfactants to OpenGate Capital

Solvay’s transformation to a specialties company has taken another step forward with an agreement to sell its European and North American amphoteric surfactant business to US private equity firm OpenGate Capital.

The business, which employs about 175 people, is a key player in surfactants, with a focus on producing amphoterics primarily used in body care, hair care and home care products.

The sale includes three main production sites in Genthin, Germany, Halifax, UK, and University Park, Illinois, USA, as well as a tolling business in Turkey. It also includes tolling and service agreements with OpenGate “to ensure a seamless transition and minimal customer disruption.”

“This agreement represents another critical step in the execution of our strategic plan as we further focus our home & personal care portfolio on growing specialty formulations and custom solutions,” said Michael Radossich, president of Solvay's Novecare global business unit.

The transaction is expected to close by end March, pending completion of customary conditions and regulatory approvals.

Solvay said it will invest the proceeds of the sale in its strategic growth segments “as part of its portfolio simplification journey.”

Last November, Solvay agreed to sell its barium and strontium business in Germany, Spain and Mexico, as well as its sodium percarbonate business in Germany, to Latour Capital. Earlier that month, the Belgian group also revealed it was negotiating the sale of its process materials business with Composites One.

On Jan. 31, 2020, Solvay completed the sale of its performance polyamide activities to BASF and Domo Chemicals.

Author: Elaine Burridge, Freelance Journalist

Solvay has agreed to sell its European and North American amphoteric surfactant...
Solvay has agreed to sell its European and North American amphoteric surfactant business to OpenGate Capital. The sale includes three main production sites in Genthin, Germany, Halifax, UK, and University Park, Illinois, USA, as well as a tolling business in Turkey. (c) Solvay

Company

Logo:

Solvay

Rue du Prince Albert 33
1050 Bruxelles
Belgium

Company contact







Interview

Stability in Motion
Strategic Response to a Shifting Pharma Landscape

Stability in Motion

Stefan Oelrich, Member of the Board of Management and President Pharmaceuticals, Bayer, discusses navigating external volatility, reshaping its internal structures, and investing in future-ready capabilities to ensure sustainable growth.

Free Expert Insights

Dual‑Targeting Breakthroughs
Advancements in Bispecific Antibody Development

Dual‑Targeting Breakthroughs

Unlock the latest breakthroughs in bispecific antibody development! Download Wiley’s free Expert Insights eBook to explore cutting-edge dual-targeting strategies, advanced purification methods, and bioanalytical technologies transforming immunotherapy and cancer treatment.

most read

Photo
28.07.2025 • NewsChemistry

VCI Welcomes US-EU Customs Deal

The German Chemical Industry Association (VCI) welcomes the fact that Ursula von der Leyen, President of the European Commission, and US President Donald Trump have averted the danger of a trade war for the time being.